Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

Gopal, Ajay K., Rajendran, Joseph G., Petersdorf, Stephen H., Maloney, David G., Eary, Janet F., Wood, Brent L., Gooley, Theodore A., Bush, Sharon A., Durack, Lawrence D., Martin, Paul J., Matthews, Dana C., Appelbaum, Frederick R., Bernstein, Irwin D., Press, Oliver W. · 2002 · Blood

Abstract

Relapsed mantle cell lymphoma is a radiation-sensitive malignancy that is unlikely to be cured by treatment with conventional high-dose therapy and autologous stem cell transplantation. We tested the safety and efficacy of using a CD20-specific monoclonal antibody conjugated with 131I to deliver high-dose radiation selectively to all lymphoma sites. Patients with relapsed or refractory mantle cell lymphoma received infusions of 131I-labeled CD20-specific monoclonal antibody (Tositumomab). The antibody dose was 1.7 mg/kg body weight, and the amount of 131I was calibrated to deliver 20 to 25 Gy to vital normal organs. This treatment was followed 10 days later by administration of high-dose etoposide (30-60 mg/kg), cyclophosphamide (60-100 mg/kg), and infusion of cryopreserved autologous stem cells. The 16 patients in this study had received a median of 3 prior treatments, and 7 had chemotherapy-resistant disease. The median dose of 131I was 510 mCi (18.87 GBq). There were no therapy-related deaths. Among the 11 patients with conventionally measurable disease at the time of treatment, the respective complete and overall response rates were 91% and 100%. Fifteen patients remain alive, and 12 have had no progression of lymphoma at 6 to 57 months from transplantation and 16 to 97 months from diagnosis. Overall survival at 3 years from transplantation is estimated at 93%, and progression-free survival is estimated at 61%. High-dose treatment with 131I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v99.9.3158

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 208

Metadata

Authors
Gopal, A. K., Rajendran, J. G., Petersdorf, S. H., Maloney, D. G., Eary, J. F., Wood, B. L., Gooley, T. A., Bush, S. A., Durack, L. D., Martin, P. J., Matthews, D. C., Appelbaum, F. R., Bernstein, I. D., & Press, O. W.
Venue
Blood
Published
2002-05-01
Volume
99
Issue
9
Pages
3158-3162
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2123185965
Cited by
208
References
1
FWCI
13.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. https://app.cochat.ai/papers/10.1182/blood.v99.9.3158
The paper
Gopal, A. K., Rajendran, J. G., Petersdorf, S. H., Maloney, D. G., Eary, J. F., Wood, B. L., Gooley, T. A., Bush, S. A., Durack, L. D., Martin, P. J., Matthews, D. C., Appelbaum, F. R., Bernstein, I. D., & Press, O. W. (2002). High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. https://doi.org/10.1182/blood.v99.9.3158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.